TL;DR
- FDA’s Recognition List 066 updates the medical-device consensus standards the agency recognizes for premarket review.
- Changes include important standards related to biological evaluation, manufacturer-supplied information, cardiovascular devices, dialysis and connected/device technology.
- Recognition of a standard does not automatically make it mandatory for every device.
- The practical risk is discovering during submission assembly that an active protocol or declaration uses an outdated edition.
- Device companies should run a standards-impact assessment against open development and testing programs now
What FDA Changed
FDA’s Recognition List Number 066 modifies the list of voluntary consensus standards it recognizes for use in medical-device regulatory work. The Federal Register notice explains that manufacturers may use recognized standards and declarations of conformity to help address certain premarket requirements.
CDRH listed the update among its August 21 regulatory developments, with Federal Register publication dated August 24.
The underlying update includes multiple standards across important device disciplines.
Why Standards Recognition Matters
A recognized consensus standard can allow a manufacturer to show that part of its device evaluation follows a framework FDA accepts.
But three details matter:
Which edition?
To what extent does FDA recognize it?
Does FDA specify transition arrangements or limitations?
A company that writes “complies with ISO XYZ” without controlling the exact recognized version can create ambiguity.
Where the Operational Risk Appears
Consider a device whose biocompatibility program started two years ago.
The protocol references the version recognized at that time.
The product development program runs for three years.
By submission, FDA’s recognized edition has changed.
Does the company need to repeat every test?
Probably not automatically.
But it does need a defensible assessment of whether the existing evidence remains adequate under the current regulatory framework.
That assessment is much easier to perform before testing than after.
Standards Change Control Should Look Like Regulatory Change Control
A mature process should map:
Standard → Old version → New recognized version → Affected devices → Open protocols → Completed tests → Submission impact → Action
This should involve more than regulatory affairs.
Depending on the standard, include:
- engineering;
- toxicology;
- software;
- cybersecurity;
- labeling;
- validation;
- supplier quality;
- external test laboratories.
The External Laboratory Problem
A test laboratory may continue using its internally validated protocol based on an older edition.
The lab may be technically competent.
The report may still create a regulatory gap if the manufacturer expected conformity with a newer FDA-recognized version.
Therefore purchase orders and test requests should specify:
- standard;
- edition;
- applicable clauses;
- deviations;
- acceptance criteria.
Do not outsource the regulatory version decision to the lab.
Recognized Does Not Mean Mandatory
This distinction is essential.
FDA recognition does not mean every medical device must comply with every recognized standard.
Standards are one mechanism manufacturers can use to address regulatory requirements.
Alternative evidence may be acceptable when scientifically justified.
The mistake is treating voluntary standards as universal law—or, at the opposite extreme, treating changes as irrelevant.
What Should Device Companies Check Now?
Run a portfolio scan against:
- active test protocols;
- not-yet-started tests;
- completed reports intended for upcoming submissions;
- declarations of conformity;
- design input documents;
- internal SOP references;
- supplier requirements;
- laboratory contracts.
Prioritize submissions planned in the next 6–12 months.
What Evidence Should Exist?
For any standard that changed, maintain a documented decision such as:
“Testing was conducted to Edition X. FDA now recognizes Edition Y. Gap analysis dated XX/XX/2026 concluded that sections A, B and C changed; existing evidence remains adequate because…”
That is significantly stronger than simply leaving the older edition in the file and hoping nobody asks.
Frequently Asked Questions
Does FDA require every recognized standard?
No. Recognition generally provides a voluntary way to support applicable regulatory requirements.
What is Recognition List 066?
It is FDA’s latest modification to the list of consensus standards recognized for use in medical-device regulatory submissions.
Do completed tests need to be repeated whenever FDA recognizes a newer edition?
Not automatically. Manufacturers should assess differences and determine whether existing evidence remains adequate.
Who should own standards monitoring?
Regulatory should coordinate it, but engineering, quality, laboratories and technical SMEs often need to assess actual impact.
When should the assessment occur?
Ideally before new testing begins and again before submission assembly.